Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-lipoic Acid in Diabetic Ischemic Cardiomyopathy
NCT06056687Completed
- Sponsor
- Damanhour University
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in ischemic cardiomyopathy (ICM) comparing Alpha Lipoic Acid Group with Placebo Group (2 arms). Primary endpoints: C-reactive protein at 3 months, Tumor necrosis factor alpha at 3 months and 3 more. Started Mar 2023; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT06056687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056687.